Identification of Herpes Simplex Virus (HSV) Shedding in the Female Genital Tract of Pregnant and Nonpregnant Women by GeneXpert PCR, Routine PCR, and Culture



Status:Recruiting
Conditions:Infectious Disease
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:19 - Any
Updated:2/10/2019
Start Date:January 2014
End Date:September 2019
Contact:Ilet Dale, RN
Email:idale@peds.uab.edu
Phone:205-934-2424

Use our guide to learn which trials are right for you!

Device Trial: Identification of Herpes Simplex Virus (HSV) Shedding in the Female Genital Tract of Pregnant and Nonpregnant Women by GeneXpert PCR, Routine PCR, and Culture

PCR detection of HSV DNA shedding in the female genital tract using the GeneXpert system
(Cepheid, Sunnyvale CA) will be compared with traditional (routine) PCR (pregnant and
nonpregnant women) and with HSV culture (nonpregnant women). The GeneXpert system performs
all sample-processing steps and real-time PCR in a single integrated cartridge. The standard
cartridge is an inexpensive disposable plastic cartridge with filtration and ultrasonic lysis
capabilities. It consists chiefly of several combined molded plastic components: a cartridge
body containing eleven fluid reservoirs or chambers along with an attached PCR tube, a
specialized valve body with an ultrasonic interface containing a sub-micron filter and glass
lysis beads, and a rotary valve with an axial syringe barrel. The operation of the cartridge
is simple. The rotary valve contains an inlet and an outlet port. Fluid such as a sample
buffer can be drawn up into a syringe drive through the inlet port of the rotary valve and
then dispensed into any other chamber within the cartridge by rotating the valve and
expelling the fluid through the outlet port. The fluid can either be passed through a filter
contained within the valve assembly or it can be passed directly into the next chamber
without filtration, depending on the path that is chosen. The cartridge fluidics and
subsequent real-time PCR all are performed within the GeneXpert instrument. The GeneXpert
contains multiple modules (ICORE units) that can be independently programmed to drive the
syringe/rotary valve, and to perform four-color real-time PCR. Each cartridge fits inside one
module, and all processing, PCR, and analysis steps are performed automatically. Each ICORE
module can be run and analyzed independently, so batching of samples is unnecessary.

The GeneXpert HSV PCR test will be validated against HSV viral cultures and routine
quantitative PCR. Validation will occur in two populations: 1) nonpregnant women in STI
clinics with clinically-apparent HSV lesions (Group 1, n=300), and 2) pregnant women in
active labor with no visible evidence of HSV infection (Group 2, n=12,500). All testing of
samples on the GeneXpert platform, routine quantitative PCR, and viral culture will be done
at the UAB Central Laboratory. Women in each group will have specimens obtained from genital
lesions (Group 1) or vaginal swabs (Group 2). Specimens from all women in Group 1 will be
evaluated by HSV culture, routine HSV PCR, and GeneXpert HSV PCR. Approximately half of the
women in Group 2 will be tested by routine HSV PCR and GeneXpert HSV PCR; specimens from the
rest of the women in Group 2 will be stored for possible testing in the future by routine HSV
PCR and GeneXpert HSV PCR. In this manner, we will maximize the data from which to compare
GeneXpert PCR results with routine PCR, while maintaining flexibility to ensure an adequate
number of specimens are positive for HSV DNA by routine PCR.

Swabs from pregnant women in labor will be placed in viral transport media, frozen at -20°C,
and batch-shipped to the UAB Central Laboratory for analysis on the GeneXpert instrument and
by routine HSV quantitative PCR. Swabs from nonpregnant women in STI clinics will be placed
in viral transport media, refrigerated at 4°C, and shipped to the UAB Central Laboratory for
real time analysis on the GeneXpert instrument and by HSV culture and routine quantitative
HSV PCR. Specimens from the first 300 women enrolled in Group 2 will be run as individual
routine PCRs and in batches of 5 samples per PCR run. In this manner, we will validate that
the level of detection from batching of samples for routine PCR is acceptable. Once this
validation occurs, specimens from the approximately half of remaining Group 2 women will be
batched for real-time routine PCR analysis. If a batch run of 5 specimens is negative, no
further testing will be performed. If a batch run of 5 specimens is positive, all of the
specimens will be separated out for re-running as individual PCRs. All specimens evaluated by
routine PCR will also be evaluated by GeneXpert PCR; in this manner, we will have individual
routine PCR results results for comparison against GeneXpert PCR results.

A blood specimen will be obtained from each nonpregnant (Group 1) and pregnant (Group 2)
woman at the time of enrollment, and if she is determined to be shedding HSV by routine PCR,
GeneXpert PCR, or culture then type-specific serologic testing will be performed. Correlation
of viral typing from the virologic sampling with HSV-1 and HSV-2 serostatus will allow for
categorization of infection (first-episode primary, first-episode nonprimary, or recurrent
infection).

Those women in Group 1 who have a positive HSV culture will be contacted directly when the
result is known. Women in Group 2 with a positive HSV PCR result will not be contacted
because routine HSV PCR and GeneXpert PCR are not FDA-cleared tests in this population; thus,
we will not know the test performance characteristics (e.g., sensitivity, specificity, etc.)
until completion of the trial. All pregnant women in Group 2 will receive written materials
at the time of enrollment educating them on signs and symptoms of neonatal HSV disease. All
postpartum women will be contacted by telephone 60-90 days post-delivery and an inquiry will
be made to determine if their babies developed neonatal HSV disease.

Data on the incidence of neonatal HSV disease among babies delivered to women in Group 2 will
be compared with the incidence data from Brown et al.1 In their study of almost 60,000 women
conducted over a 20 year period, this group of researchers has reported an incidence rate for
neonatal HSV disease of 1 in 3,200 live births.

Inclusion Criteria:•Signed Informed Consent from woman

•≥ 19 years of age

- Female gender

- In active labor with a viable fetus, OR non-pregnant and being evaluated in STI
clinics for herpetic genital lesions

Exclusion Criteria:•For women in active labor, active herpetic lesions in the genital
region

- Receipt of acyclovir, valacyclovir, or famciclovir within the previous 14 days

- Known HIV infection
We found this trial at
15
sites
111 Michigan Ave NW
Washington, District of Columbia
(202) 476-5000
Childrens National Medical Center As the nation’s children’s hospital, the mission of Children’s National Medical...
?
mi
from
Washington,
Click here to add this to my saved trials
1720 2nd Ave S
Birmingham, Alabama 35233
(205) 934-4011 
Principal Investigator: David Kimberlin, M.D.
Phone: 205-934-5316
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
529 West Markham Street
Little Rock, Arkansas 72205
(501) 686-7000
Principal Investigator: Jose Romero, MD
Phone: 501-364-1416
University of Arkansas for Medical Sciences The University of Arkansas for Medical Sciences (UAMS) in...
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
601 Elmwood Avenue
Rochester, New York 14642
(585) 275-2100
Principal Investigator: Mary Caserta, M.D.
Phone: 585-275-5944
Univ of Rochester Medical Center One of the nation's top academic medical centers, the University...
?
mi
from
Rochester, NY
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Andrea (Andi) Shane, M.D., M.P.H.
Phone: 404-727-4044
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Aurora, Colorado 80045
Principal Investigator: Mark J Abzug, M.D.
Phone: 720-777-6389
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Charlotte, North Carolina 28203
Principal Investigator: Amina Ahmed, M.D.B.S.
Phone: 704-381-6870
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
2500 Metrohealth Dr
Cleveland, Ohio 44109
(216) 778-7800
Principal Investigator: Nazha F Abughali, M.D.
Phone: 216-778-3402
MetroHealth Med Ctr The MetroHealth System is one of the largest, most comprehensive health care...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Columbus, Ohio 43205
Principal Investigator: Pablo Sanchez, MD
Phone: 614-355-5724
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Lebanon, New Hampshire 03765
?
mi
from
Lebanon, NH
Click here to add this to my saved trials
?
mi
from
Manhasset, NY
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15224
Principal Investigator: Harold Wiesenfeld, MD
Phone: 412-692-6786
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Salt Lake City, Utah 84132
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Shreveport, Louisiana 71130
Principal Investigator: John Vanchiere, MD, PhD
Phone: 318-675-7877
?
mi
from
Shreveport, LA
Click here to add this to my saved trials